F. Furnari, T. Fenton, R. Bachoo, A. Mukasa, J. Stommel et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes & Development, vol.21, issue.21, pp.2683-2710, 2007.
DOI : 10.1101/gad.1596707

D. Parsons, S. Jones, X. Zhang, J. Lin, R. Leary et al., An Integrated Genomic Analysis of Human Glioblastoma Multiforme, Science, vol.321, issue.5897, pp.1807-1812, 2008.
DOI : 10.1126/science.1164382

L. Salmena, A. Carracedo, and P. Pandolfi, Tenets of PTEN Tumor Suppression, Cell, vol.133, issue.3, pp.403-414, 2008.
DOI : 10.1016/j.cell.2008.04.013

W. Shen, A. Balajee, J. Wang, H. Wu, C. Eng et al., Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity, Cell, vol.128, issue.1, pp.157-170, 2007.
DOI : 10.1016/j.cell.2006.11.042

V. Schreiber, F. Dantzer, J. Ame, G. De-murcia, and . Poly, Poly(ADP-ribose): novel functions for an old molecule, Nature Reviews Molecular Cell Biology, vol.116, issue.7, pp.517-528, 2006.
DOI : 10.1038/nrm1963

URL : https://hal.archives-ouvertes.fr/hal-00129983

B. Gibson and W. Kraus, New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs, Nature Reviews Molecular Cell Biology, vol.10, issue.7, pp.411-424, 2012.
DOI : 10.1038/nrm3376

H. Bryant, N. Schultz, H. Thomas, K. Parker, D. Flower et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.20, issue.7035, pp.913-917, 2005.
DOI : 10.1016/S0022-2836(03)00313-9

H. Farmer, N. Mccabe, C. Lord, A. Tutt, D. Johnson et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.11, issue.7035, pp.917-921, 2005.
DOI : 10.1177/1087057103008003013

N. Mccabe, N. Turner, C. Lord, K. Kluzek, A. Bialkowska et al., Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition, Cancer Research, vol.66, issue.16, pp.8109-8115, 2006.
DOI : 10.1158/0008-5472.CAN-06-0140

P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu et al., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, issue.2, pp.361123-134, 2009.

C. Sun, F. Zhang, T. Xiang, Q. Chen, T. Pandita et al., Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers, Oncotarget, vol.5, issue.10, pp.3375-3385, 2014.
DOI : 10.18632/oncotarget.1952

K. Ha, W. Fiskus, D. Choi, S. Bhaskara, L. Cerchietti et al., Histone deacetylase inhibitor treatment induces ???BRCAness??? and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells, Oncotarget, vol.5, issue.14, pp.5637-5650, 2014.
DOI : 10.18632/oncotarget.2154

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170637

J. Murai, Y. Zhang, J. Morris, J. J. Takeda, S. Doroshow et al., Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition, Journal of Pharmacology and Experimental Therapeutics, vol.349, issue.3, pp.408-416, 2014.
DOI : 10.1124/jpet.113.210146

M. Venere, P. Hamerlik, Q. Wu, R. Rasmussen, L. Song et al., Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells, Cell Death and Differentiation, vol.47, issue.2, pp.258-269, 2014.
DOI : 10.1111/j.1744-7348.1939.tb06990.x

D. Van-vuurden, E. Hulleman, O. Meijer, L. Wedekind, M. Kool et al., PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation, Oncotarget, vol.2, issue.12, pp.984-996, 2011.
DOI : 10.18632/oncotarget.362

B. Mcellin, C. Camacho, B. Mukherjee, B. Hahm, N. Tomimatsu et al., PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors, Cancer Research, vol.70, issue.13, pp.5457-5464
DOI : 10.1158/0008-5472.CAN-09-4295

A. Mendes-pereira, S. Martin, R. Brough, A. Mccarthy, J. Taylor et al., Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors, EMBO Mol Med, vol.1, pp.6-7315, 2009.

B. Mcellin, C. Camacho, B. Mukherjee, B. Hahm, N. Tomimatsu et al., PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors, Cancer Research, vol.70, issue.13, pp.5457-5464, 2010.
DOI : 10.1158/0008-5472.CAN-09-4295

E. Galan-moya, L. Guelte, A. , L. Fernandes, E. Thirant et al., Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway, EMBO reports, vol.19, issue.5, pp.470-476, 2011.
DOI : 10.1038/sj.onc.1208311

A. Castiel, L. Visochek, L. Mittelman, Y. Zilberstein, F. Dantzer et al., Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells, Journal of Visualized Experiments, issue.78, p.50568, 2013.
DOI : 10.3791/50568

A. Castiel, L. Visochek, L. Mittelman, F. Dantzer, S. Izraeli et al., A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells, BMC Cancer, vol.26, issue.6, p.412, 2011.
DOI : 10.1038/sj.onc.1210879

A. Sgorbissa, A. Tomasella, H. Potu, I. Manini, and C. Brancolini, Type I IFNs signaling and apoptosis resistance in glioblastoma cells Apoptosis : an international journal on programmed cell death, pp.1229-1244, 2011.

D. Baker, M. Dawlaty, T. Wijshake, K. Jeganathan, L. Malureanu et al., Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan, Nature Cell Biology, vol.19, issue.1, pp.96-102, 2013.
DOI : 10.1182/blood-2010-02-268391

D. Weinstock, K. Nakanishi, H. Helgadottir, and M. Jasin, Assaying Double???Strand Break Repair Pathway Choice in Mammalian Cells Using a Targeted Endonuclease or the RAG Recombinase, Methods Enzymol, vol.409, pp.524-540, 2006.
DOI : 10.1016/S0076-6879(05)09031-2

M. Park, M. Kim, I. Park, H. Kang, H. Yoo et al., PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer research, pp.6318-6322, 2002.

M. Clark, N. Homer, O. Connor, B. Chen, Z. Eskin et al., U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line, PLoS Genetics, vol.19, issue.1, p.1000832, 2010.
DOI : 10.1371/journal.pgen.1000832.s009

R. Ricke and J. Van-deursen, Aneuploidy in health, disease, and aging, The Journal of Cell Biology, vol.61, issue.1, pp.11-21, 2013.
DOI : 10.1371/journal.pgen.1002719

M. Lampson and T. Kapoor, The human mitotic checkpoint protein BubR1 regulates chromosome???spindle attachments, Nature Cell Biology, vol.62, issue.1, pp.93-98, 2005.
DOI : 10.1083/jcb.137.7.1567

A. Musacchio and E. Salmon, The spindle-assembly checkpoint in space and time, Nature Reviews Molecular Cell Biology, vol.6, issue.5, pp.379-393, 2007.
DOI : 10.1038/nrm2163

Y. Ding, C. Hubert, J. Herman, C. P. Toledo, C. Skutt-kakaria et al., Cancer-Specific Requirement for BUB1B/BUBR1 in Human Brain Tumor Isolates and Genetically Transformed Cells, Cancer Discovery, vol.3, issue.2, pp.198-211, 2013.
DOI : 10.1158/2159-8290.CD-12-0353

D. Hegan, Y. Lu, G. Stachelek, M. Crosby, R. Bindra et al., Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130, Proceedings of the National Academy of Sciences, vol.107, issue.5, pp.2201-2206, 2010.
DOI : 10.1073/pnas.0904783107

L. Tentori, L. Ricci-vitiani, A. Muzi, F. Ciccarone, F. Pelacchi et al., Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide, BMC Cancer, vol.72, issue.1, p.151, 2014.
DOI : 10.1007/s00280-013-2175-0

URL : https://hal.archives-ouvertes.fr/pasteur-01164062

J. Tang, D. Svilar, R. Trivedi, X. Wang, E. Goellner et al., N-methylpurine DNA glycosylase and DNA polymerase ?? modulate BER inhibitor potentiation of glioma cells to temozolomide, Neuro-Oncology, vol.13, issue.5, pp.471-486, 2011.
DOI : 10.1093/neuonc/nor011

L. Galluzzi, I. Vitale, J. Abrams, E. Alnemri, E. Baehrecke et al., Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012, Cell Death and Differentiation, vol.94, issue.1, pp.107-120, 2012.
DOI : 10.1083/jcb.200712051

I. Vitale, L. Galluzzi, M. Castedo, and G. Kroemer, Mitotic catastrophe: a mechanism for avoiding genomic instability, Nature Reviews Molecular Cell Biology, vol.29, issue.6, pp.385-392, 2011.
DOI : 10.1038/nrm3115

M. Ali, B. Telfer, C. Mccrudden, M. O-'rourke, H. Thomas et al., Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?, Clinical Cancer Research, vol.15, issue.19, pp.6106-6112, 2009.
DOI : 10.1158/1078-0432.CCR-09-0398

A. Robaszkiewicz, Z. Valko, K. Kovacs, C. Hegedus, E. Bakondi et al., The role of p38 signaling and poly(ADP-ribosyl)ation-induced metabolic collapse in the osteogenic differentiation-coupled cell death pathway, Free Radical Biology and Medicine, vol.76, pp.69-79, 2014.
DOI : 10.1016/j.freeradbiomed.2014.07.027

A. Antolin and J. Mestres, Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors, Oncotarget, vol.5, issue.10, pp.3023-3028, 2014.
DOI : 10.18632/oncotarget.1814

C. Patru, L. Romao, P. Varlet, L. Coulombel, E. Raponi et al., CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors, BMC Cancer, vol.4, issue.5, p.66, 2010.
DOI : 10.1016/j.stem.2009.03.003

URL : https://hal.archives-ouvertes.fr/inserm-00663773

G. Lamm, P. Steinlein, M. Cotten, and G. Christofori, A rapid, quantitative and inexpensive method for detecting apoptosis by flow cytometry in transiently transfected cells, Nucleic Acids Research, vol.25, issue.23, pp.4855-4857, 1997.
DOI : 10.1093/nar/25.23.4855